SCS Traditional denied due to quantity / dose limits by eviCore healthcare?

NACC-aligned. Conservative therapy >=6 weeks, BHE clearance, >=50% trial relief documented for SCS implant.

Submit eviCore PA retroactively with full clinical. Psychologist letter explicitly stating 'appropriate candidate per NACC criteria.' Trial diary: daily NRS, ODI pre/post, analgesic reduction, patient global impression.

## Why eviCore Flags Traditional SCS for Quantity Limits

Traditional spinal cord stimulation (SCS) involves an implanted pulse generator and lead system. eviCore, which manages prior authorization and utilization review on behalf of many health plans, applies quantity or component restrictions to SCS implants — typically limiting the number of leads, extensions, or trial-versus-permanent components that can be authorized in a single episode of care. A quantity-limits denial usually means the submitted request exceeded those component counts or requested an additional device within a defined lookback window.

## Why This Denial Is Appealable

Quantity limits must be clinically justified for your specific anatomy, lead placement requirements, and the treating physician's documented plan of care. If your physician determined that a particular configuration is medically necessary — for example, because your pain distribution requires a specific lead arrangement — that clinical rationale creates a strong basis for appeal. Coverage policies cannot override individualized medical necessity determinations without a meaningful review.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under your plan's ERISA §503 procedures (for employer-sponsored plans) or applicable state law.
• External review: Under ACA §2719, adverse benefit determinations on medical necessity grounds are subject to binding independent external review. The external-review request window is generally up to four months from the denial notice — check your Explanation of Benefits for the exact deadline.
• Expedited review: If your condition is urgent (e.g., you are in the trial phase and the implant window is closing), request expedited internal and external review simultaneously.

## Documentation to Gather

1. Diagnosis confirmation — imaging, neurological evaluation, and the specific pain diagnosis supporting SCS candidacy. 2. Prior treatment history — a dated, outcome-noted list of all conservative and interventional treatments tried and failed, matching the requirements in eviCore's published clinical guidelines for SCS. 3. Clinical severity — office notes, pain-scale documentation, and functional-status assessments from the chart. 4. Prescriber medical-necessity letter — your implanting physician should explain in writing why the specific component configuration is required, citing the FDA-approved device labeling and eviCore's own published coverage criteria. 5. Device labeling — the FDA-approved Instructions for Use (IFU) for the specific SCS system, which defines indicated configurations.

## Criteria-Mapping Approach

Request a copy of eviCore's current clinical coverage guideline for SCS. List every requirement. For each one, write the exact chart fact that satisfies it — dates, treatment names, and outcomes. For the quantity question specifically, document why the requested component count is the minimum necessary per the device's IFU and the physician's operative plan. Submit this as a structured exhibit so the reviewer can match each criterion to your evidence without interpretation.